Myriad, ACLU Square Off At Gene Patent Hearings

Law360, New York (February 2, 2010, 3:36 PM EST) -- Balking at allegations that it had attempted to patent human thought, Myriad Genetics Inc. on Tuesday urged a federal judge to consider only the language of the patent laws as written when determining the validity of the company's patents covering isolated human genes.

Myriad, accused by medical groups and the American Civil Liberties Union of wrongly patenting the isolation and study of DNA strands linked to breast and ovarian cancer, defended its inventions as “new and useful” processes during hearings on the parties' cross-motions for summary...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.